China Pharma Holdings (CPHI) Non-Current Assets (2010 - 2026)

China Pharma Holdings (CPHI) has reported Non-Current Assets for 17 consecutive years, with $42.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets rose 285.9% year-over-year to $42.7 million; the trailing twelve-month figure through Jun 2026 stood at $128.0 million (up 192.34% YoY), and the FY2025 full-year result was $28.7 million, up 146.64% from the prior year.
• Non-Current Assets retreated to $42.7 million in Q2 2026 per CPHI's latest filing, from $43.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $43.1 million in Q1 2026 and bottomed at $9.5 million in Q3 2023.
• Historically, Non-Current Assets has averaged $15.6 million across 5 years, with a median of $11.3 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Non-Current Assets declined 24.53% in 2022, then soared 285.9% in 2026.
• Over 5 years, Non-Current Assets stood at $11.8 million in 2022, then retreated by 11.4% to $10.5 million in 2023, then increased by 10.93% to $11.6 million in 2024, then soared by 146.64% to $28.7 million in 2025, then soared by 49.04% to $42.7 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $42.7 million, $43.1 million, and $28.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.